Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression

Metabolism: Clinical and Experimental

Volumn 58, Issue 1, 2009, Pages 109-119

  Kong, Wei Jia ^a   Zhang, Hao ^a   Song, Dan Qing ^a   Xue, Rong ^b   Zhao, Wei ^b   Wei, Jing ^c   Wang, Yue Ming ^a   Shan, Ning ^b   Zhou, Zhen Xian ^b   Yang, Peng ^a   You, Xue Fu ^a   Li, Zhuo Rong ^a   Si, Shu Yi ^a   Zhao, Li Xun ^a   Pan, Huai Ning ^c   Jiang, Jian Dong ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Nanjing Second Hospital   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; GLUCOSE; INSULIN; INSULIN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL CULTURE; MALE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; RNA TRANSCRIPTION; TIME;

ANIMALS; BERBERINE; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED NOD; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 57049090579     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.08.013     Document Type: Article

References (41)

1. Gonzalez-Sanchez J.L., and Serrano-Rios M. Molecular basis of insulin action. Drug News Perspect 20 (2007) 527-531
2. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
3. Taylor S.I., Accili D., and Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?. Diabetes 43 (1994) 735-740
4. Foti D., Chiefari E., Fedele M., et al. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat Med 11 (2005) 765-773
5. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
6. Otto C., Lehrke M., and Goke B. Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics 3 (2002) 99-116
7. Vasudevan A.R., and Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 6 (2004) 850-863
8. Phillips L.S., Grunberger G., Miller E., et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24 (2001) 308-315
9. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
10. Guan Y., Hao C., Cha D.R., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11 (2005) 861-866
11. Luo L.J. Experience of berberine in the treatment of diarrhea. Chin J Med 41 (1955) 452-455
12. Kong W., Wei J., Abidi P., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 (2004) 1344-1351
13. Kong W.J., Liu J., and Jiang J.D. Human low-density lipoprotein receptor gene and its regulation. J Mol Med 84 (2006) 29-36
14. Abidi P., Zhou Y., Jiang J.D., et al. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 25 (2005) 2170-2176
15. Chen Q.M., and Xie M.Z. Studies on the hypoglycemic effect of Coptis chinensis and berberine. Yao Xue Xue Bao 21 (1986) 401-406
16. Ni Y.X. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi 8 (1988) 711-713
17. Nakamaru K., Matsumoto K., Taguchi T., et al. AICAR, an activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells. Biochem Biophys Res Commun 328 (2005) 449-454
18. Reed M.J., Meszaros K., Entes L.J., et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49 (2000) 1390-1394
19. Hanson R.L., Pratley R.E., Bogardus C., et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151 (2000) 190-198
20. Whetzel A.M., Bolick D.T., Srinivasan S., et al. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 99 (2006) 731-739
21. Mitchell P.J., and Tjian R. Transcriptional regulation in mammalian cells by sequence specific DNA binding proteins. Science 245 (1989) 371-378
22. Araki E., Shimada F., Uzawa H., et al. Characterization of the promoter region of the human insulin receptor gene. J Biol Chem 262 (1987) 16186-16191
23. Pascoe W.S., and Storlien L.H. Inducement by fat feeding of basal hyperglycemia in rats with abnormal beta-cell function. Model for study of etiology and pathogenesis of NIDDM. Diabetes 39 (1990) 226-233
24. Joshi R.L., Lamothe B., Cordonnier N., et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 15 (1996) 1542-1547
25. Kitamura T., Kitamura Y., Nakae J., et al. Mosaic analysis of insulin receptor function. J Clin Invest 113 (2004) 209-219
26. Fisher S.J., and Kahn C.R. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 111 (2003) 463-468
27. Seino S., Seino M., Nishi S., et al. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A 86 (1989) 114-118
28. Lee Y.S., Kim W.S., Kim K.H., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55 (2006) 2256-2264
29. Nishino Y., Miura T., Miki T., et al. Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 61 (2004) 610-619
30. Yamamoto R., Kobayashi H., Yanagita T., et al. Up-regulation of cell surface insulin receptor by protein kinase C-alpha in adrenal chromaffin cells: involvement of transcriptional and translational events. J Neurochem 75 (2000) 672-682
31. Foti D., Iuliano R., Chiefari E., et al. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol Cell Biol 23 (2003) 2720-2732
32. Brunetti A., Manfioletti G., Chiefari E., et al. Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI (Y). FASEB J 15 (2001) 492-500
33. Banks G.C., Li Y., and Reeves R. Differential in vivo modifications of the HMGI (Y) nonhistone chromatin proteins modulate nucleosome and DNA interactions. Biochemistry 39 (2000) 8333-8346
34. Bard-Chapeau E.A., Hevener A.L., Long S., et al. Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. Nat Med 11 (2005) 567-571
35. Evans R.M., Barish G.D., and Wang Y.X. PPARs and the complex journey to obesity. Nat Med 10 (2004) 355-361
36. Eckel R.H. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320 (1989) 1060-1068
37. Jensen M.D., Caruso M., Heiling V., et al. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes 38 (1989) 1595-1601
38. Kim J.K., Fillmore J.J., Chen Y., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 98 (2001) 7522-7527
39. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103 (1999) 253-259
40. Grundy S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5 (2006) 295-309
41. Rollason V., and Vogt N. Reduction of polypharmacy in the elderly: systematic review of the role of pharmacist. Drugs Aging 20 (2003) 817-832